Telix

Jul 7
2 min

Telix Receives FDA Feedback on Phase 3 Trial Design for Prostate Cancer Therapy Product

Summary of FDA Feedback FDA has provided feedback on the design of Telix’s Phase 3 PROSTACT trial of TLX591 (177Lu- DOTA-rosopatamab) for...

54 viewsWrite a comment

Remora Capital

Jan 8
3 min

TELIX: Acceleration of Prostate Cancer Therapy Program

Synopsis: In conjunction with the completion of the acquisition of Atlab Pharma SAS (ASX release: 11/09/18) Telix instigated an audit of ...

18 viewsWrite a comment

Remora Capital

Dec 26, 2019
1 min

TELIX: NDA Clinical Briefing Package Submitted to the US FDA

Melbourne (Australia) – 27th December 2019. Telix Pharmaceuticals Limited (ASX: TLX), is pleased to announce that it has submitted a comp...

12 viewsWrite a comment

Remora Capital

Oct 13, 2019
2 min

Telix Pharmaceuticals and GE Healthcare : Maximising 68Ga Supply for Prostate Cancer Imaging

Melbourne (Australia) – 14 October 2019. Telix Pharmaceuticals Limited (ASX:TLX, “Telix”, the “Company”) a clinical-stage biopharmaceutic...

9 viewsWrite a comment

Remora Capital

Aug 27, 2019
4 min

TELIX: FDA Pre-NDA Meeting Outcomes : TLX591-CDx (illumet ™)

TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET).

69 viewsWrite a comment

Remora Capital

Jul 22, 2019
4 min

Telix Pharmaceuticals Reports Positive Consultation for European Approval of Prostate Imaging Agent

Program relevance: TLX591-CDx (68Ga-PSMA-11) for the imaging of metastatic prostate cancer with positron emission tomography (PET) Synops...

6 viewsWrite a comment

Remora Capital

May 31, 2019
3 min

Telix Pharmaceuticals and Emory Winship Cancer Institute to Collaborate on Clinical Trial

Program relevance: TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET). Branded as illumetT...

4 viewsWrite a comment

Remora Capital

May 29, 2019
3 min

TELIX: Prostate Imaging Program (illumetTM) : Commercial and Regulatory Update

TLX591-CDx (68Ga-PSMA) for the imaging of prostate cancer with positron emission tomography (PET). Branded as illumetTM in the US market.

10 viewsWrite a comment

Remora Capital

Apr 24, 2019
3 min

TELIX: Fractionated Prostate Cancer Therapy Data Published, Significant Treatment Benefit

Date: 26th April, 2019 Program relevance: TLX591 (Prostate Therapy), TLX591-CDx (Prostate Imaging) Synopsis: The development of TLX591 is...

7 viewsWrite a comment

Remora Capital

Jan 24, 2019
5 min

Telix Group Expands Prostate Imaging Capability through ININ Technology Partnership

Program relevance: TLX591 (Therapy) / TLX591-CDx (Imaging) Synopsis: Telix is developing prostate cancer imaging technology as part of it...

5 viewsWrite a comment

Remora Capital

Jan 8, 2019
6 min

TELIX: Strategy Update – Acceleration of Prostate Cancer Therapy Program

Program relevance: TLX591 Synopsis: In conjunction with the completion of the acquisition of Atlab Pharma SAS (ASX release: 11/09/18) Tel...

7 viewsWrite a comment

Remora Capital

Sep 12, 2018
5 min

Telix Pharmaceuticals Completes Acquisition of Atlab Pharma

Melbourne (Australia) and Nantes (France) – 11 September 2018. Telix Pharmaceuticals Limited (“Telix”, the “Company”) today announced the...

29 viewsWrite a comment

Telix Receives FDA Feedback on Phase 3 Trial Design for Prostate Cancer Therapy Product

TELIX: Acceleration of Prostate Cancer Therapy Program

TELIX: NDA Clinical Briefing Package Submitted to the US FDA

Telix Pharmaceuticals and GE Healthcare : Maximising 68Ga Supply for Prostate Cancer Imaging

TELIX: FDA Pre-NDA Meeting Outcomes : TLX591-CDx (illumet ™)

Telix Pharmaceuticals Reports Positive Consultation for European Approval of Prostate Imaging Agent

Telix Pharmaceuticals and Emory Winship Cancer Institute to Collaborate on Clinical Trial

TELIX: Prostate Imaging Program (illumetTM) : Commercial and Regulatory Update

TELIX: Fractionated Prostate Cancer Therapy Data Published, Significant Treatment Benefit

Telix Group Expands Prostate Imaging Capability through ININ Technology Partnership

TELIX: Strategy Update – Acceleration of Prostate Cancer Therapy Program

Telix Pharmaceuticals Completes Acquisition of Atlab Pharma

TELIX: FDA Pre-NDA Meeting Outcomes : TLX591-CDx (illumet ™)